Announcements Trials
Browse Landscape

Phase

Phase 1/2 4Phase 2 3Phase 1 3Phase NA 1

Status

Completed 6Active not recruiting 4Recruiting 3Unknown 2Withdrawn 1Not yet recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3Plasma cell 2Other hematologic neoplasm 1

Conditions

Carcinoma, Non-Small-Cell Lung 173Leukemia, Myeloid, Acute 152Breast Neoplasms 146Neoplasms 143Neoplasm Metastasis 142Colorectal Neoplasms 137Recurrence 105Ovarian Neoplasms 101Pancreatic Neoplasms 83Advanced Solid Tumor 82Lung Neoplasms 81Multiple Myeloma 77Prostatic Neoplasms 75Advanced Solid Tumors 74Stomach Neoplasms 73Squamous Cell Carcinoma of Head and Neck 72Carcinoma, Hepatocellular 68Glioblastoma 65Melanoma 64Lymphoma, Non-Hodgkin 64Triple Negative Breast Neoplasms 59Lymphoma, B-Cell 55Endometrial Neoplasms 54Myelodysplastic Syndromes 53Precursor Cell Lymphoblastic Leukemia-Lymphoma 52Lymphoma 52Glioma 51Brain Neoplasms 46Carcinoma, Renal Cell 44Hematologic Neoplasms 43

Interventions

fludarabine 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × Recruiting × Immune System Diseases × Clear all
NCT07075185 2026-04-24

inMMyCAR

Kelonia Therapeutics, Inc.

Phase 1 Recruiting
70 enrolled
LymphoidPlasma cell

Blood Protein Disorders, Disease, Hematologic Diseases, Immune System Diseases, Immunoproliferative Disorders, Lymphoproliferative Disorders, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Paraproteinemias, Vascular Diseases, Hemostatic Disorders

NCT05963217 2025-07-02

Study of TBI-2001(Autologous CD19 Specific Chimeric Antigen Receptor (CAR) Gene-transduced T Lymphocytes) for Relapsed or Refractory CD19+ B-cell Lymphoma, CLL/SLL

University Health Network, Toronto

Phase 1 Recruiting
19 enrolled
LymphoidOther hematologic neoplasm

Immune System Diseases, Lymphoma, Neoplasms, Neoplasms by Histologic Type, Neoplasms, Experimental, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

NCT06271252 2024-08-02

A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study

OriCell Therapeutics Co., Ltd.

Phase 1 Recruiting
81 enrolled
LymphoidPlasma cell

Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, Hemorrhagic Disorders, Immune System Diseases, Immunoproliferative Disorders, Lymphoproliferative Disorders, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Paraproteinemias, Vascular Diseases, Hemostatic Disorders, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡